Álvarez-López H, Ruiz-Gastélum E, Díaz-Aragón A

Idioma: Inglés [English version]
Referencias bibliográficas: 24
Paginas: s242-246
Archivo PDF: 304.69 Kb.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Clinical review on triglycerides. Eur Heart J. 2020; 41 (1): 99-109c.

2. Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003; 361 (9374): 2005-2016.

3. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364 (9435): 685-696.

4. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41 (1): 111-188.

5. Toth PP, Shah PK, Lepor NE. Targeting hypertriglyceridemia to mitigate cardiovascular risk: A review. Am J Prev Cardiol. 2020; 3: 100086.

6. Iqbal Z, Ho JH, Adam S, France M, Syed A, Neely D et al. Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK. Atherosclerosis. 2020; 313: 126-136.

7. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls S, et al. Perkovic, V. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010; 375 (9729): 1875-1884.

8. Ray KK, Corral P, Morales E, Nicholls SJ. Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. Lancet. 2019; 394 (10199): 697-708.

9. Mauri M, Calmarza P, Ibarretxe D. Dyslipemias and pregnancy, an update. Clin Investig Arterioscler. 2021; 33 (1): 41-52.

10. Simha V. Management of hypertriglyceridemia. BMJ. 2020; 371: m3109.

11. Oh RC, Trivette ET and Westerfield KL. Management of hypertriglyceridemia: common question and answers. Am Fam Physician. 2020; 102 (6): 347-354.

12. Santos-Baez LS and Ginsberg HN (2020) Hypertriglyceridemia-Causes, Significance, and Approaches to Therapy. Front. Endocrinol. 11:616. NICE Clinical Guideline CG 181 (2014) Cardiovascular disease: risk assessment and reduction, including lipid modification. Available in: https://www.nice.org.uk/guidance/cg181

13. Pradhan AD, Paynter NP, Everett BM, Glynn RJ, Amarenco P, Elam M et al. Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with Diabetes (PROMINENT) study. Am Heart J. 2018; 206: 80-93.

14. Skulas-Ray A, Wilson P, Harris W, Brinton E, Kris-Etherton P, Richter C et al. Omega-3 fatty acids for the management of hypertriglyceridemia. A science advisory from the American Heart Association. Circulation. 2019; 140: e673-e691.

15. Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T et al. Effects of pemafibrate, a novel selective PPARα Modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, Phase 3 Trial. Diabetes Care. 2018; 41 (3): 538-546.

16. Schandelmaier S, Briel M, Saccilotto R, Olu KK, Arpagaus A, Hemkens LG, Nordmann AJ. Niacin for primary and secondary prevention of cardiovascular events. Cochrane Database Syst Rev. 2017; (6): CD009744.

17. Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L et al. Omega-3 treatment trialists' collaboration. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77,917 individuals. JAMA Cardiol. 2018; 3 (3): 225-234.

18. Khan MS, Ishaq M, Ayub MT, Rehman AU, Hayes JJ, Mortada M, Biederman RW. The novelty of icosapent ethyl in the management of hypertriglyceridemia and alleviating cardiovascular risk. J Lipids. 2021; 2021: 6696915.

19. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB et al. REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019; 380 (1): 11-22.

20. Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ et al. Effect of high-dose omega-3 fatty acids vs. corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020; 324 (22): 2268-2280.

21. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019; 73 (24): 3168-3209.

22. Peterson BE, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA et al. REDUCE-IT Investigators. Reduction in revascularization with icosapent ethyl: insights from REDUCE-IT revascularization analyses. Circulation. 2021: 143 (1): 33-44.

23. Patel PN, Patel SM, Bhatt DL. Cardiovascular risk reduction with icosapent ethyl. Curr Opin Cardiol. 2019; 34 (6): 721-727.

24. Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012; 97 (9): 2969-2989.